| Next 10 |
Ad
NVO News and Press Novo Nordisk A/S
News | Novo Nordisk A/S (NYSE:NVO)
-
2024-12-13 05:03:00 ET Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations. Investing in a stock at a steep premium can limit the return you can earn from it, or worse, result in a significant loss in the event of slowing marke...
-
2024-12-12 10:01:00 ET Summary Pioneer Fund’s Class Y Shares returned 3.79% in the quarter, underperforming the 5.89% return of the Fund’s benchmark, the SPX. At the sector level, security selection accounted for all of the underperformance in the period with stock s...
-
2024-12-12 09:32:12 ET More on Novo Nordisk Novo Nordisk: Just The Right Price (Rating Upgrade) Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals ...
-
2024-12-12 09:00:00 ET Summary The equity market volatility during the third quarter of 2024 attracted plenty of attention and expert conjecture. During the quarter, the Harbor International Compounders ETF returned 4.10%, underperforming its primary benchmark. During the quar...
-
2024-12-12 09:00:00 ET Summary The third quarter of 2024 was, once again, a positive one in absolute terms in most markets. The Harbor Diversified International All-Cap Fund performed broadly in line with its benchmark, the MSCI All Country World Ex. US (ND) Index, during the quar...
-
2024-12-11 13:54:23 ET More on Catalent Catalent wins EU approval for planned $16.5B sale to Novo Holdings Catalent gains amid report buyer working on contact extensions with drugmakers Seeking Alpha’s Quant Rating on Catalent Historical earnings data ...
-
2024-12-11 11:12:32 ET Summary For the first time since I initiated coverage on the Danish weight loss treatments company Novo Nordisk earlier this year, it's now attractive enough to be upgraded to a Buy. Fears of a slump in its blockbuster weight loss treatment, Wegovy's sales i...
-
2024-12-11 07:55:00 ET Summary The Allspring Premier Large Company Growth Fund outperformed the Russell 1000 Growth Index in Q3, driven by strong security selection in IT and industrials. Market sentiment shifted dramatically in Q3 2024, with a sharp downturn in August followed by...
-
2024-12-11 06:10:00 ET Summary The fund underperformed the MSCI EAFE Index (Net) for the quarter, with positive contributions from energy and materials sectors but lagging in financials and consumer discretionary. Market volatility was driven by geopolitical tensions, central bank...
-
2024-12-10 17:01:32 ET More on AbbVie, Amgen, etc. Regeneron: Recent Bear Run May Be Justified - Pharma Faces A Testing 2025 Johnson & Johnson Is A Better Dividend Stock Than Amgen In Our View Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healt...
Stock Information
Get NVO Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
-
2024-12-13 05:03:00 ET Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations. Investing in a stock at a steep premium can limit the return you can earn from it, or worse, result in a significant loss in the event of slowing marke...
-
2024-12-10 04:10:00 ET One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the company reported solid results from trials of a candidate meant to address one of today's hottest growth areas: weight loss. The weight loss drug mar...
-
2024-12-09 04:59:00 ET According to a sneak peek of the data from one of Eli Lilly 's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly powerful arch-rival, Novo Nordisk , (NYSE: NVO) and it...